Neurology News

With stock market volatility likely to remain high until the COVID-19 crisis ends, many investors, including physicians, are concerned about the unpredictability of portfolios’ performance. At the same time, bank account, CD and treasury yields are near all-time lows.

Early and short-term rituximab may be an option to treat patients with certain forms of autoimmune encephalitis, according to study results published in Neurology: Neuroimmunology & Neuroinflammation.

Changes in blood-based biomarkers suggested long-duration spaceflight may pose risks for humans, according to a research letter published in JAMA Neurology.

A virtual reality intervention called “Bear Blast” significantly decreased pain and anxiety among children and teenagers while they underwent peripheral IV catheter placement, trial data showed.

Healthline Media recently announced the launch of its Conscious Language Guide, a tool that health care professionals can use to communicate with patients in a more “empathetic and non-stigmatizing” way, according to the organization.

Adults with autism spectrum disorder were about 2.6 times more likely to be diagnosed with early-onset dementia than adults in the general population, according to a case control study published in Autism Research.

More than 50% of individuals with thrombosis and thrombocytopenia syndrome linked to COVID-19 vector-based vaccine administration presented with cerebral venous sinus thrombosis, according to a study.

Higher tissue 2-hydroxyglutarate concentration appeared to increase risk for preoperative seizures in isocitrate dehydrogenase 1/2 mutant tumors, according to study results published in Neurology.

The FDA has granted breakthrough therapy designation to gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, as an Alzheimer’s disease treatment.

Amzell BV, a specialty pharmaceutical development company, announced it has a special protocol assessment agreement with the FDA for a phase 3 trial of its injectable infantile epileptic disease therapy.